46 related articles for article (PubMed ID: 12639725)
1. Dual impairment of GABAA- and GABAB-receptor-mediated synaptic responses by autoantibodies to glutamic acid decarboxylase.
Mitoma H; Ishida K; Shizuka-Ikeda M; Mizusawa H
J Neurol Sci; 2003 Apr; 208(1-2):51-6. PubMed ID: 12639725
[TBL] [Abstract][Full Text] [Related]
2. Pathophysiological Effects of Autoantibodies in Autoimmune Encephalitides.
Ryding M; Mikkelsen AW; Nissen MS; Nilsson AC; Blaabjerg M
Cells; 2023 Dec; 13(1):. PubMed ID: 38201219
[TBL] [Abstract][Full Text] [Related]
3. An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes.
Peng Y; Yang H; Xue YH; Chen Q; Jin H; Liu S; Yao SY; Du MQ
Front Neurol; 2023; 14():1209302. PubMed ID: 37859648
[TBL] [Abstract][Full Text] [Related]
4. Catecholaminergic and cholinergic neuromodulation in autism spectrum disorder: A comparison to attention-deficit hyperactivity disorder.
Koevoet D; Deschamps PKH; Kenemans JL
Front Neurosci; 2022; 16():1078586. PubMed ID: 36685234
[TBL] [Abstract][Full Text] [Related]
5. A Breakdown of Immune Tolerance in the Cerebellum.
Hampe CS; Mitoma H
Brain Sci; 2022 Feb; 12(3):. PubMed ID: 35326284
[TBL] [Abstract][Full Text] [Related]
6. Advances in the Pathogenesis of Auto-antibody-Induced Cerebellar Synaptopathies.
Mitoma H; Manto M
Cerebellum; 2023 Feb; 22(1):129-147. PubMed ID: 35064896
[TBL] [Abstract][Full Text] [Related]
7. Immune-Mediated Cerebellar Ataxias: Clinical Diagnosis and Treatment Based on Immunological and Physiological Mechanisms.
Mitoma H; Manto M; Hadjivassiliou M
J Mov Disord; 2021 Jan; 14(1):10-28. PubMed ID: 33423437
[TBL] [Abstract][Full Text] [Related]
8. Fundamental Mechanisms of Autoantibody-Induced Impairments on Ion Channels and Synapses in Immune-Mediated Cerebellar Ataxias.
Mitoma H; Honnorat J; Yamaguchi K; Manto M
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668612
[TBL] [Abstract][Full Text] [Related]
9. GAD antibodies in neurological disorders - insights and challenges.
Graus F; Saiz A; Dalmau J
Nat Rev Neurol; 2020 Jul; 16(7):353-365. PubMed ID: 32457440
[TBL] [Abstract][Full Text] [Related]
10. Neurological Syndromes Associated with Anti-GAD Antibodies.
Dade M; Berzero G; Izquierdo C; Giry M; Benazra M; Delattre JY; Psimaras D; Alentorn A
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32456344
[TBL] [Abstract][Full Text] [Related]
11. Distinct Effects of Stereotactically Injected Human Cerebrospinal Fluid Containing Glutamic Acid Decarboxylase Antibodies into the Hippocampus of Rats on the Development of Spontaneous Epileptic Activity.
Frerker B; Rohde M; Müller S; Bien CG; Köhling R; Kirschstein T
Brain Sci; 2020 Feb; 10(2):. PubMed ID: 32098388
[No Abstract] [Full Text] [Related]
12. Anti-GAD Antibodies and the Cerebellum: Where Do We Stand?
Manto M; Mitoma H; Hampe CS
Cerebellum; 2019 Apr; 18(2):153-156. PubMed ID: 30343467
[TBL] [Abstract][Full Text] [Related]
13. Immune-mediated Cerebellar Ataxias: Practical Guidelines and Therapeutic Challenges.
Mitoma H; Manto M; Hampe CS
Curr Neuropharmacol; 2019; 17(1):33-58. PubMed ID: 30221603
[TBL] [Abstract][Full Text] [Related]
14. Physiological and Morphological Principles Underpinning Recruitment of the Cerebellar Reserve.
Kakei S; Ishikawa T; Lee J; Honda T; Hoffman DS
CNS Neurol Disord Drug Targets; 2018; 17(3):184-192. PubMed ID: 29546837
[TBL] [Abstract][Full Text] [Related]
15. Acute Cerebellar Ataxia Associated with Anti-glutamic Acid Decarboxylase Antibodies Mimicking Miller Fisher Syndrome.
Nakamura Y; Nakajima H; Hosokawa T; Yamane K; Ishida S; Kimura F
Intern Med; 2018 Jan; 57(2):269-271. PubMed ID: 29093402
[TBL] [Abstract][Full Text] [Related]
16. Immune-mediated cerebellar ataxias: from bench to bedside.
Mitoma H; Manto M; Hampe CS
Cerebellum Ataxias; 2017; 4():16. PubMed ID: 28944066
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic Roles of Glutamic Acid Decarboxylase 65 Autoantibodies in Cerebellar Ataxias.
Mitoma H; Manto M; Hampe CS
J Immunol Res; 2017; 2017():2913297. PubMed ID: 28386570
[TBL] [Abstract][Full Text] [Related]
18. Anti-GAD65 Containing Cerebrospinal Fluid Does not Alter GABAergic Transmission.
Hackert JK; Müller L; Rohde M; Bien CG; Köhling R; Kirschstein T
Front Cell Neurosci; 2016; 10():130. PubMed ID: 27242441
[TBL] [Abstract][Full Text] [Related]
19. Disease-specific monoclonal antibodies targeting glutamate decarboxylase impair GABAergic neurotransmission and affect motor learning and behavioral functions.
Manto M; Honnorat J; Hampe CS; Guerra-Narbona R; López-Ramos JC; Delgado-García JM; Saitow F; Suzuki H; Yanagawa Y; Mizusawa H; Mitoma H
Front Behav Neurosci; 2015; 9():78. PubMed ID: 25870548
[TBL] [Abstract][Full Text] [Related]
20. Consensus Paper: Neuroimmune Mechanisms of Cerebellar Ataxias.
Mitoma H; Adhikari K; Aeschlimann D; Chattopadhyay P; Hadjivassiliou M; Hampe CS; Honnorat J; Joubert B; Kakei S; Lee J; Manto M; Matsunaga A; Mizusawa H; Nanri K; Shanmugarajah P; Yoneda M; Yuki N
Cerebellum; 2016 Apr; 15(2):213-32. PubMed ID: 25823827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
